[REVISION HISTORY]
US FDA commissioner nomination process
3 recorded revisions of this situation.
What changed
2026-11-18 04:23 UTC → 2026-11-18 13:56 UTC ·
added
removed
The nomination of Dr. Heidi Overton to lead the Food and Drug Administration (FDA) has faced significant political scrutiny. Nominated by President Donald Trump, Overton encountered opposition from Republican Senator Bill Cassidy, pro-life activists regarding abortion pill safety, and vaccine skeptics. As the Senate confirmation process continued, Congressional Republicans discussed Senator Roger Marshall as a potential alternative nominee. This consideration followed opposition to Overton from moderate Republicans and anti-abortion groups. Republican leadership faced time constraints to confirm a nominee before Democrats assumed the Senate majority in January. The White House has officially withdrawn the nomination of Dr. Heidi Overton. The decision follows significant opposition from Senate Republicans and concerns regarding her ability to secure the necessary votes for confirmation. Senator Bill Cassidy, chair of the Senate Health, Education, Labor, and Pensions Committee, had expressed reservations about Overton’s scientific independence and her willingness to challenge the administration on issues such as childhood vaccine schedules. Additionally, Overton faced scrutiny from both sides of the aisle regarding her stance on reproductive rights, specifically concerning the medication abortion pill mifepristone. Following the withdrawal, reports indicate that Republicans are considering Senator Roger Marshall, a physician who recently lost his reelection bid in Kansas, as a potential replacement nominee for the agency. The withdrawal occurred one day before a scheduled vote by the Senate Health, Education, Labor, and Pensions Committee. Beyond concerns over vaccine schedules, Senator Cassidy also cited a lack of managerial experience. Furthermore, supporters of the “Make America Healthy Again” (MAHA) movement, led by Health Secretary Robert F. Kennedy Jr., expressed skepticism regarding her ability to challenge corporate interests. The FDA has remained without a permanent commissioner since the resignation of Dr. Marty Makary in May.
Versions
- 2026-11-18 13:56 UTC US FDA commissioner nomination process
- 2026-11-18 04:23 UTC US FDA commissioner nomination process
- 2026-11-18 02:02 UTC US FDA commissioner nomination process
- 2026-11-17 17:14 UTC US FDA commissioner nomination process
Select a version to see what changed compared to the one before it.